The generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.
Perrigo Co. (Nasdaq: PRGO) Monday announced that it has closed the acquisition of Velcera Inc., the Yardley, Pa.-based pet health products company, for $160 million in cash.
Perrigo Co. (Nasdaq: PRGO) Monday announced that it has begun shipments of Guaifenesin 600mg Extended-Release tablets in a launch to its retail and wholesale customers
Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.
Perrigo Company (Nasdaq: PRGO) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%. Perrigo’s NDA included a bioequivalence study that compared its product to AbbVie’s AndroGel 1%.
The Allegan generic drugmaker Perrigo Co. Friday record revenue of $883 million for its second fiscal quarter ended Dec. 29, up from $838.2 million in the same quarter a year earlier. Net income for the quarter was $106 million or $1.12 a share, up from $99.7 million or $1.06 aa share in the same quarter a year earlier.
Perrigo Co. (Nasdaq: PRGO) Thursday announced that its board of directors declared a quarterly dividend of 9 cents a share.
Allegan’s Perrigo Co., the world’s largest makers of store brand infant formulas, Friday announced a new packaging look with new features.
The Perrigo Company (Nasdaq: PRGO) announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).
Perrigo Co. Tuesday announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced.